Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Pharmalot
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Biotech venture capital had a record-breaking quarter, but isn’t out of the woods yet

  • Kate Sheridan

By Kate Sheridan April 9, 2020

Reprints
revenues folder
Adobe

A version of this story also appeared in STAT’s daily biotech newsletter, The Readout. Subscribe here.

Biotech venture capitalists and their portfolio companies had a historic first quarter — but that doesn’t mean the industry is out of the woods just yet.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Kate Sheridan

Kate Sheridan

Research Reporter

Kate collects and analyzes documents, data, and other information for biotech, health tech, science, and politics stories.

Tags

Stanford scientist who broke genome sequencing record on what…
Stanford scientist who broke genome sequencing record on what faster diagnoses mean for patients
How one medical school became remarkably diverse — without…
How one medical school became remarkably diverse — without considering race in admissions
Long-term study shows most prostate cancer patients don’t need…
Long-term study shows most prostate cancer patients don’t need aggressive treatment
J&J loses a patent battle in India over a…
J&J loses a patent battle in India over a crucial tuberculosis drug
Pharmalittle: FDA panel backs conditional approval for Biogen ALS…
Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs

Recommended Stories